Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Diabetes
Eligibility Criteria
Inclusion Criteria:
- Males and females with type 2 diabetes, 18-70 years of age at Visit 1
- Managing diabetes with diet and exercise only or currently being treated with a stable dose of metformin (at least 1500 mg/day)
- Glycosylated hemoglobin at Visit 1 between 7.5% and 10.0%, if on metformin and between 7.5% and 10.9%, if without treatment
- Body mass index (BMI) ≥ 23.0 kg/m^2 and ≤ 45.0 kg/m^2 at Visit 1
Exclusion Criteria:
- Females who are pregnant or breast-feeding
- Known medical history or presence of type 1 diabetes or acute metabolic diabetic complications, unstable or rapidly progressing retinopathy, nephropathy or neuropathy
- Acute coronary syndrome or uncontrolled hypertension
- Does not meet all diet or previous/concomitant medication restriction criteria
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Experimental
Experimental
Experimental
Active Comparator
Placebo Comparator
JTT-851 Dose 1
JTT-851 Dose 2
JTT-851 Dose 3
Glimepiride Dose 1
Placebo active & Placebo comparator
JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
Active Comparator Capsule and Placebo Tablets, administered once daily for 12 weeks
Placebo Tablets for study drug and Placebo Capsule for active comparator, administered once daily for 12 weeks